Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally

Abstract

Previous studies have shown greater atrophy in grey and white matter of various brain regions in patients with Parkinson's disease with mild cognitive impairment than in those without. These anatomical differences likely account for the distinct clinical profiles observed between those groups, but do not account for the evolution of regional brain degradation observed as the disease evolves. Although we have shown recently that cortical thinning correlates significantly more with disease duration in Parkinson's patients with mild cognitive impairment than in those without, to the best of our knowledge no study to date has explored this longitudinally. The present study investigated the longitudinal changes of the cortical and subcortical grey matter in patients with Parkinson's disease with and without mild cognitive impairment. Additionally, these two groups were compared with healthy controls. We found a higher rate of cortical thinning in the temporal, occipital, parietal and supplementary motor area, in patients with Parkinson's disease with mild cognitive impairment compared with both cognitively stable patients and healthy controls. On the other hand cognitively stable patients had only one lateral occipital and one fusiform cluster with increased rate of thinning compared with healthy individuals. Correlating the rate of change of cortical thickness with the results of Montreal Cognitive Assessment scores revealed significant thinning associated with cognitive decline in the group of all patients, in similar regions including temporal and medial occipital lobe. Finally, a significant decrease in the volume of the amygdala and nucleus accumbens was observed specifically in patients with Parkinson's disease with mild cognitive impairment. These results indicate that the early presence of mild cognitive impairment in patients with Parkinson's disease is associated with a faster rate of grey matter thinning in various cortical regions as well as a significant diminishment of limbic subcortical structures. This specific pattern of brain degradation associated with the early presence of mild cognitive impairment might serve as a marker of development toward dementia.

Monitoring of 30 marker candidates in early Parkinson disease as progression markers

“…Voxel-based morphometry (VBM) of gray matter and hippocampus by 1.5T volumetric MRI was included because significant atrophy has been described in correlation with PD progression and cognitive decline. 15 We also investigated serum urate. 16 We tested known CSF markers that have been previously discussed as potential diagnostic markers of PD state or its progression, including total a-synuclein (a-syn), b-amyloid 1-42, total and phosphorylated tau protein (t-tau and p-tau), as well as neurofilament light chain proteins.…”

Cognitive deficits in Parkinson’s disease: current perspectives

“…95,96 Longitudinal studies of patients with PD-MCI have shown that these areas progressively lose volume and this correlates with cognitive deficit. 95,97 By the time PDD is diagnosed, there is significant thinning of the parietal, occipital, frontal and temporal regions, plus further atrophy of the hippocampus, parahippocampus, insular and cingulate. 98,99 Diffusion tensor imaging (DTI) has revealed evidence of reduced structural connectivity in similar regions -in …”

Reproducibility of Deep Gray Matter Atrophy Rate Measurement in a Large Multicenter Dataset

“…[7][8][9][10] More recently, research revealed that deep GM atrophy specifically plays an important role in the characterization, course, and progression of AD [11][12][13][14][15][16][17] and in other diseases like MS [18][19][20] and Parkinson disease. [21][22][23] Measurements of deep GM atrophy could therefore be of importance in the evaluation of neuroprotective treatment (eg, in investigating drug efficacy). Currently, a growing number of clinical trials are incorporating brain volume changes as an early biomarker.…”